Has Aimee Hiltbold, MD received payments from drug or device companies?

Yes. Drug and device makers reported $28,982 in general payments to Aimee Hiltbold, MD across 117 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Aimee Hiltbold, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Aimee Hiltbold, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Aimee Hiltbold, MD

Cardiovascular Disease · New Orleans, LANPI 1003173568

Payments from drug & device makers

What this record shows

The money is spread across several categories — travel and lodging (36.8%), grants and food and beverage — rather than concentrated in one kind of arrangement. 10 manufacturers reported payments, led by Boston Scientific at 55.9% of the total. Reporting peaked in 2019 at $14,698 and has fallen 58.0% since, to $6,173 in 2025. Among cardiovascular disease clinicians in LA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$28,982in general payments, 2019–2025

Across 117 payments — averaging $247.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Boston Scientific$16K
Abbott$6K
Medtronic$5K
Biotronik Inc.$2K
Philips North America LLC$162
EBR Systems, Inc.$146
plus $86 from 4 others

What the payments were for

Consulting fees$1,5005%
Speaking & faculty fees$2,77510%
Grants$8,62130%
Travel & lodging$10,66837%
Food & beverage$5,16418%
Education$2541%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Boston Scientific	35	$16,203
Abbott	40	$5,689
Medtronic	16	$4,547
Biotronik Inc.	16	$2,150
Philips North America LLC	4	$162
EBR Systems, Inc.	1	$146
E.r. Squibb & Sons, L.L.C.	2	$35
Kiniksa Pharmaceuticals, Ltd.	1	$19
Biosense Webster, Inc.	1	$17
Sanofi-aventis U.S. LLC	1	$15

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

GENERAL BRADY$7,500
GENERAL - THERAPIES$5,610
AVEIR$2,411
ENSITE PRECISION$1,205
RHYTHMIA$1,193
Micra$1,097
GENERAL TACHY$901
TACTICATH ABLATION CATHETER, SENSOR ENABLED$554
GENERAL - STRUCTURAL HEART$220
HeartMate 3 Left Ventricular Dev$172
OMNIASECURE MRI SURESCAN$152
AURORA EV-ICD MRI SURESCAN$125
EnSite Precision Cardiac Mapping System$118
LUX-DX$114

How this compares

$28,982 in reported general payments places this provider in the 90th percentile of 281 cardiovascular disease providers in Louisiana.

See all cardiovascular disease providers in Louisiana →

Medicare billing

Part B allowed, 2024

$112,341

Medicare patients

425

Services billed

1,164

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
EliquisApixaban	412	$319,190
XareltoRivaroxaban	81	$64,345
EntrestoSacubitril/Valsartan	17	$15,152
Dofetilide	14	$6,339
Flecainide Acetate	119	$4,018
Amiodarone Hcl	206	$3,237
Metoprolol Succinate	272	$2,723
SotalolSotalol Hcl	69	$1,047
Diltiazem 24hr Er (Cd)Diltiazem Hcl	37	$713
Verapamil SrVerapamil Hcl	12	$683
Propafenone Hcl	11	$290
Carvedilol	33	$212
Warfarin Sodium	23	$131
Metoprolol Tartrate	16	$90
Losartan Potassium	11	$87

Paid to pharmacies, not to this prescriber.

Other cardiovascular disease in New Orleans

Keith FerdinandNew Orleans$239K
Carl LavieNew Orleans$228K
Alexandra SanchezNew Orleans$69K
Nabeel SaghirNew Orleans$49K
Richard MilaniNew Orleans$28K
Salima QamruddinNew Orleans$27K
Joseph EnglertNew Orleans$19K
Emmett ChapitalNew Orleans$13K
Yvonne GillilandNew Orleans$13K
Frank WilklowNew Orleans$12K

See the full list for Louisiana →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →